Treato
A 'medical intelligence' platform that used Natural Language Processing (NLP) to aggregate patient experiences from social media and forums. It collapsed after failing to monetize its data effectively and struggling to secure a buyer or new funding round.
The Autopsy
| Section | Details |
|---|---|
| Startup Profile | Founders: Gideon Mantell Funding: Raised ~$15M from investors including Reed Elsevier Ventures, Western Technology Investment, and New Leaf Venture Partners |
| Cause of Death | Market Fit: Monetization Struggle: While the data was interesting to patients, pharmaceutical companies (the primary target) were slow to pay for 'social listening' data that lacked clinical validation Other: Regulatory Uncertainty: Increasing scrutiny on data privacy and the harvesting of health information from public forums made their business model riskier. Funding Exhaustion: The company failed to close a strategic sale or a follow-on investment round, leading to an immediate shutdown of their New Jersey and Israel offices |
| The Critical Mistake | Quality over Quantity: Treato focused on the volume of patient voices but struggled to filter out the 'noise' and misinformation inherent in online forums, which limited the data's value for high-stakes medical decision-making. |
| Key Lessons |
|
Deep Dive
Treato was founded on a powerful premise: the real experts on drug side effects and treatments are the patients living with them. By 2016, the platform had indexed over 2 billion patient posts from across the web. It offered a search engine where users could see how others reacted to specific medications, creating a 'Voice of the Patient' map that was theoretically invaluable to both consumers and pharmaceutical researchers. The B2B Pivot Failure Initially, Treato was popular as a consumer tool. However, like many HealthTech startups, they realized the real money was in B2B. They launched 'Treato IQ,' a tool designed to help pharmaceutical companies understand how their drugs were perceived in the real world. The hope was that Pharma would use this for marketing and drug development. But the highly regulated nature of the industry meant companies were hesitant to act on 'unstructured' social media data that wasn't gathered in a controlled environment. The Data Privacy Wall As the company looked to scale, the global conversation around data privacy shifted. The introduction of GDPR in Europe and heightened awareness of data harvesting made the practice of scraping health forums more controversial. For potential acquirers, the legal risk of owning a database of identifiable health discussions outweighed the technological benefits of Treato's NLP engine. The Sudden Exit By mid-2018, Treato's runway had ended. The company had attempted to find a strategic partner to keep the servers running, but when negotiations failed, the board moved to liquidate. The website was shuttered, and the 'wisdom' of billions of patient posts was effectively taken offline overnight. Treato remains a case study in the difficulty of turning 'Social Big Data' into a sustainable healthcare business.
Key Lessons
In HealthTech, 'Patient Sentiment' is a nice-to-have, but 'Clinical Evidence' is what pays the bills
Data-scraping businesses are highly vulnerable to platform policy changes and evolving privacy laws (like GDPR)
Selling to Big Pharma requires long lead times and deep integration; a standalone dashboard is rarely enough to sustain a venture-backed burn rate